| Mpa Group Nfp, Ltd. | |
|
1217 S Euclid Ave Bay City MI 48706-3311 | |
| (989) 667-9661 | |
| (989) 667-9680 |
| Full Name | Mpa Group Nfp, Ltd. |
|---|---|
| Speciality | Social Worker |
| Location | 1217 S Euclid Ave, Bay City, Michigan |
| Authorized Official Name and Position | Ronald Leix (CEO) |
| Authorized Official Contact | 9896679661 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Mpa Group Nfp, Ltd. 1217 S Euclid Ave Bay City MI 48706-3311 Ph: (989) 667-9661 | Mpa Group Nfp, Ltd. 1217 S Euclid Ave Bay City MI 48706-3311 Ph: (989) 667-9661 |
| NPI Number | 1174741649 |
|---|---|
| Provider Enumeration Date | 04/23/2007 |
| Last Update Date | 08/22/2020 |
| Medicare PECOS PAC ID | 1951499805 |
|---|---|
| Medicare Enrollment ID | O20071112000070 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174741649 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Primary |
| 104100000X | Social Worker | (* (Not Available)) | Primary |
| Provider Name | Masroor U Haq |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1417064502 PECOS PAC ID: 8820983927 Enrollment ID: I20040218000204 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Michelle Richards |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1851421887 PECOS PAC ID: 6901862986 Enrollment ID: I20041202000320 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Joseph M Dula |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1295841088 PECOS PAC ID: 7911095864 Enrollment ID: I20071112000104 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Patricia L Straney |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1891820338 PECOS PAC ID: 3678661527 Enrollment ID: I20071112000126 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Marilyn H Draper |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1710028089 PECOS PAC ID: 7911183074 Enrollment ID: I20110525000645 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Kathryn A Dean |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1295860757 PECOS PAC ID: 6800970369 Enrollment ID: I20120207000500 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Rachel Prenzler |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1417267873 PECOS PAC ID: 5698935930 Enrollment ID: I20120324000054 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Kacie R Schuette |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1891037537 PECOS PAC ID: 6608007034 Enrollment ID: I20140327000524 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Trisha Taylor Mclemore |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1568850196 PECOS PAC ID: 3870818552 Enrollment ID: I20150223000238 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Mary M Kelly |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1174953095 PECOS PAC ID: 1456678887 Enrollment ID: I20150324002525 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Jesika R Lee |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1811325905 PECOS PAC ID: 9335467638 Enrollment ID: I20150417000314 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Zachary Y Jaime |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1013312479 PECOS PAC ID: 0840504577 Enrollment ID: I20150807015240 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Morgan M Meier |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1760882278 PECOS PAC ID: 4981997996 Enrollment ID: I20160728001885 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Emily R Simbeck |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1447689161 PECOS PAC ID: 7113201328 Enrollment ID: I20170308000945 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Celia O'mara |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1578940706 PECOS PAC ID: 6204104946 Enrollment ID: I20170621001051 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Clare C Margres |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1770966251 PECOS PAC ID: 7113288739 Enrollment ID: I20180227002568 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Erica Springer |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1821484551 PECOS PAC ID: 8123380094 Enrollment ID: I20180313002185 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Bradley Michael Fotopoulos |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1457852402 PECOS PAC ID: 1052647179 Enrollment ID: I20190727000401 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Deanna Dubay |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346898228 PECOS PAC ID: 6507196771 Enrollment ID: I20191001003334 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Nicole Benkert |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1043782865 PECOS PAC ID: 9133522667 Enrollment ID: I20210721003264 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Laura Sandy |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1811345085 PECOS PAC ID: 5294132635 Enrollment ID: I20210928000197 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
| Provider Name | Morgan Gray |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1255955704 PECOS PAC ID: 2567848724 Enrollment ID: I20220926003382 |
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
News Archive
"Try after try to make vaginal creams that could repel the AIDS virus have failed. Now researchers are testing if a drug used to treat HIV infection finally might give women a tool to prevent it - by infusing the medicine into vaginal gels and contraceptive-style rings," the Associated Press reports in a piece that examines researchers' latest efforts to create effective HIV microbicides, ahead of the biennial International Microbicides Conference next weekend.
Obesity has been identified as an adverse risk factor for survival in many adult and childhood cancers, but not in pediatric Hodgkin lymphoma, the most common cancer in adolescents.
Researchers from Rome, Italy, describe a finding in the August 2007 print issue of The FASEB Journal that could lead to new drugs to fight the HIV/AIDS virus, as well as new vaccines to prevent infection.
Sunesis Pharmaceuticals, Inc. has announced a presentation of updated interim results from an ongoing Phase 2 clinical trial demonstrating that the Company's lead product candidate, voreloxin, shows promising efficacy and safety as a single agent in patients with platinum-resistant ovarian cancer.
› Verified 3 days ago
Shinedling & Shinedling Pc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2355 And A Half Delta Rd, Bay City, MI 48706 Phone: 989-667-5654 Fax: 989-667-5330 | |
New Directions Counseling And Neurobehavioral Center, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 2355 Delta Rd, Bay City, MI 48706 Phone: 989-684-6832 Fax: 989-684-4856 | |
Rivers Edge Recovery Center Of Michigan Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 916 Washington Ave Ste 205, Bay City, MI 48708 Phone: 989-415-3143 Fax: 989-391-4412 | |
Bcb Consulting, Pllc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 721 Washington Ave, Ste 505, Bay City, MI 48708 Phone: 989-233-2725 | |
Journey Counseling Center, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 4771 2 Mile Rd Ste A, Bay City, MI 48706 Phone: 989-778-2323 Fax: 989-778-2322 | |
Michelle Trudell, Pllc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 4771 2 Mile Rd, Suite A, Bay City, MI 48706 Phone: 989-778-2323 Fax: 989-778-2322 | |
Lutheran Child And Family Service Of Michigan Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 6019 Westside Saginaw Rd, Bay City, MI 48706 Phone: 989-686-7650 Fax: 989-686-7688 |